Company Overview

Bonus BioGroup (TASE: BONS) is a biotechnology company applying a proprietary, innovative, tissue engineering technology to produce cell-based therapies. 
Bonus’ flagship products
BonoFillTM:  A personalized, viable bone graft for bone tissue repair that is specifically tailored to the biological, physical and clinical needs of each patient.
MesenCure: Bonus BioGroup has joined the global efforts to fight the novel coronavirus - COVID-19 (SARS-CoV-2) - pandemic outbreak, and is currently developing an advanced, cell therapy for the attenuation of the life-threatening acute respiratory distress in COVID-19 pneumonia.

 

BonoFillTM

Bonus BioGroup’s BonoFillTM bone graft product is an injectable, tissue-engineered, personalized, viable bone graft designed for bone reconstruction of bone deficiencies caused by trauma and various bone diseases, manufactured from the patient’s own cells, hence optimally promoting bone regeneration and the healing of the bone defect, while diminishing the probability of tissue rejection.

Bonus BioGroup’s BonoFillTM bone graft contains a unique mixture of mesenchymal stromal cells (MSCs) and bone-forming cells which harbor intrinsic regenerative capabilities and secrete a variety of growth factors involved in recruiting cells from the surrounding healthy tissue at the area of transplantation, as well as inducing vascularization for the overall optimal promotion of the bone regeneration process from within the bone graft and the surrounding tissue.

BonoFillTM entire manufacturing process takes only about two weeks, from receiving the adipose (fat) tissue, to the transplantation-ready bone graft product.

BonoFillTM first-in-human clinical trial was launched in April 2014 and demonstrated the safety and efficacy of Bonus’ tissue-engineered bone graft for the repair of oral and maxillofacial bone deficiencies.

Currently, there are two ongoing phase I/II clinical trials evaluating the safety and efficacy of BonoFillTM as therapy for bone regeneration and repair in the oral and maxillofacial indication (bone augmentation and void filling in the jaws) and in the orthopedic indication (long and short bones extra articular comminuted fractures, non-union and gap fractures).

Bonus BioGroup is striving to provide millions of patients worldwide with advanced, tissue-engineered therapies for skeletal disorders and aims to develop remedies for various types of bone trauma and diseases (e.g., complex fractures, arthritis, osteoporosis), for which, to date, there are insufficient and unsatisfactory treatment options.

 

MesenCure

Bonus BioGroup joined the global efforts to fight the COVID-19 (novel coronavirus, SARS-CoV-2) pandemic, and is currently developing an advanced, cell therapy for the alleviation of the life-threatening acute respiratory distress in COVID-19 pneumonia.

MesenCure is a cell-based product, consisting of primed mesenchymal stromal cells for the attenuation of the cytokine storm - the hyper-inflammatory immune response that can result in the life-threatening acute respiratory distress prevalent in severe COVID-19 pneumonia, as well as in other inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia, which are among the leading causes of death worldwide, after ischemic heart disease and stroke.

Bonus BioGroup developed an advanced procedure in order to prime the mesenchymal cells, isolated from healthy donors, by subjecting them to specific conditions that specifically enhance their immunomodulatory potency, while maintaining their safety.

Upon the intravenous injection of MesenCure, the cells reach the lung where they attenuate the hyper-inflammatory response and alleviate the respiratory distress, as well as promote the healing of the injured lung tissue.

Preclinical studies have demonstrated the potency of MesenCure to alleviate acute respiratory distress in animal models, and histological examination demonstrated MesenCure treated lungs to resemble healthy lungs, that did not demonstrate tissue injury or inflammation.

Currently, Bonus BioGroup is conducting a phase I/II clinical trial with MesenCure at the largest medical center in the north of Israel.

 

Bonus BioGroup – The Company

The Company was founded to commercialize over ten years of tissue engineering and bone regeneration research carried out by Dr. Shai Meretzki in cooperation with leading scientists in the field. Dr. Meretzki holds a PhD degree in biotechnology and has over 25 years of experience specifically in the field of stem cells and tissue engineering, as well as the technical know-how and proficiency in the set-up of biotech companies. Dr. Meretzki has also founded Pluristem Life Systems Inc. (NASDAQ: PSTI; TASE: PLTR), and served as its CEO and CTO bringing it from basic research to a successful clinical-stage public company. 

Bonus BioGroup’s manufacturing facility is located within the company's complex in Haifa, Israel, and supplies the company in its clinical trials. The facility, as well as all of the company's production activities, including the development stage, manufacturing, quality control and product distribution, are Good Manufacturing Practice (GMP) and ISO-9001 compliant.

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.